Form D · Other

Nurix Therapeutics, Inc.

San Francisco, CA · CIK 0001549595

Offering snapshot reported Mar 26, 2020 · SEC filing

Reported sold
$120M
Offering amount: $120M
Investors reported
23
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Mar 9, 2020
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Mar 26, 2020Initial$120,249,972No comparison23SEC filing
Sep 18, 2015Initial$17,033,334No comparison1SEC filing
Jan 2, 2014Initial$2,075,000No comparison2SEC filing
Mar 28, 2013Amendment$5,300,000$2,200,000vs May 15, 20124SEC filing
May 16, 2012Initial$1,800No comparison1SEC filing
May 15, 2012Initial$3,100,000No comparison4SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-363761

Source: Form D, filed Mar 26, 2020. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Leon Chen Director
David Goeddel Director
Mark Goldsmith Director
Julia Gregory Director
Lori Kunkel Director
Timothy Kutzkey Director, Executive
David Lacey Director
Christine Ring Executive
Arthur Sands Director, Executive
Kutzkey Timothy Director, Executive
Robert Tjian Director
Jeff Tong Director
Hans Van Houte Executive

Issuer details

Industry: Other (See others in industry)

Address:
1700 Owens Street, Suite 205
San Francisco, CA, 94158